Achieve Life Sciences, Inc.
ACHV
$5.10
$0.255.16%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.70% | 121.84% | 92.96% | 76.49% | 82.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.85% | 20.84% | 17.86% | 49.01% | 115.55% |
| Operating Income | 18.85% | -20.84% | -17.86% | -49.01% | -115.55% |
| Income Before Tax | 20.73% | -18.62% | -15.42% | -50.31% | -97.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.73% | -18.62% | -15.42% | -50.31% | -97.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.73% | -18.62% | -15.42% | -50.31% | -97.52% |
| EBIT | 18.85% | -20.84% | -17.86% | -49.01% | -115.55% |
| EBITDA | 18.91% | -20.95% | -17.96% | -49.37% | -116.57% |
| EPS Basic | 48.49% | 23.15% | 22.27% | -48.76% | -42.61% |
| Normalized Basic EPS | 46.67% | 20.86% | 20.65% | -48.53% | -42.81% |
| EPS Diluted | 48.49% | 23.15% | 22.27% | -48.76% | -42.61% |
| Normalized Diluted EPS | 46.67% | 20.86% | 20.65% | -48.53% | -42.81% |
| Average Basic Shares Outstanding | 53.90% | 54.38% | 48.50% | 1.07% | 38.47% |
| Average Diluted Shares Outstanding | 53.90% | 54.38% | 48.50% | 1.07% | 38.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |